Thu, Oct 23, 2014, 4:45 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Johnson & Johnson Message Board

  • EliasFardo EliasFardo Dec 29, 1997 5:03 PM Flag

    J&J's dirty little secret

    The January 12 issue of Forbes has an article titled "J&J's dirtly little secret" about the toxicity of acetaminophen ( Tylenol ). People die from Tylenol. One statement that was very troublesome "No other over-the-counter drug has a narrower range between therapy and toxicity than acetaminophen". There was one chart that if I read it correctly indicates that acetaminophen leads even cocaine in drug fatalities as reported to poison control centers. I am long J&J. Should I worry?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • My sincere wish is that you never have to find out why it wouldn't work for lung cancer. I can't explain it in a few sentences, but believe me, it would not work. I can see it being useful for other types of cancer, but not lung. Drop the speculation, it is painful for those of us who have to deal with the real thing.

    • Actually, it would allow the operator, either chest surgeon or pulmonologist to cut in separate areas. This is because you can mark with CARTO (Biosense) where you have been. An advantage would be that after visualize the mass, you can make sure that you are removing tissue from different parts of it.

    • EliasFardo, with the risk of boring others who read this thread, I agree with you. People should be careful. I guess my beef
      is that this is a problem that applies to all over the counter drugs. I would have liked to known the toxicity level for
      aspirin, ibuprofin, anti-histimines etc. I like Forbes too and agree that they have a good history of turning over the rocks to find
      all the bugs. One thing I am excited about is J&J's Cox II drugs, these promise to take a large hunk of the anti-inflammatory
      market which is about $5 billion a year. Their web site is very good about keeping people informed. Drug pipeline is one of the
      best.

    • It appears to be the pulmonologists (using endoscopes), not chest surgeons, who are interested in this use of Biosense, specifically to avoid the need to cut.

    • I do think that Forbes had an important point regarding tylenol. The point being that this drug which is advertised as being very safe, can become toxic in rather small dosages. This got poo poo'ed on this board which leads me to believe that some people missed two points completely. (1) Be careful of all drugs, especially with children. (2) Tylenol is advertised by J&J as being especially safe. Any threat to that perception by the public can have financial consequences.

      I have been a long time reader of Forbes. 20+ years. I generally have a high opinion of its content. However, I do think it has lost something since the old man died.

    • Use Biosense for lung cancer? Don't think so. I know where I think those chest cutters should stick the needle if that's the best they can come up with.

    • In October the ACCP (Chest Physicians) meeting had a report from Johns Hopkins about using Biosense technology in
      conjunction with a bronchoscope from a company called Vision Sciences. According to the report, uncertainty about "where to stick the
      needle" has kept a minimally invasive procedure called TBNA from being more widely used for lung cancer diagnosis. The conclusion
      was that the approach was feasible, and clinical trials are planned. So JNJ is apparently not relying solely on cardiac
      applications for the Biosense technology.

    • Here's a free one. JNJ bought Biosense, a company based out of Haifa, Israel which has a 3-D spatialization system called
      CARTO which also uses a Silicon Graphics work station. JNJ apparently paid 400 million. Developed initially for the
      electrophysiology field, works great making beautiful pictures. Unfortunately a product looking for an application. Suspect that they bought
      it to be used with transmyocardial revascularization via a catheter. Unfortunately another application which may soon go by the
      wayside if gene therapy works as anticipated (Phase I trials currently underway at Cornell?).

    • So who is stopping you. Or are you one of those lazy people who likes others to do their research for them. A breathless world awaits to see what you can come up with.

    • As a frequent viewer of this board I would appreciate less back and forth on pharmakinetics and toxicity opinions and more on relevant issues that impact this company. While the tylenol franchise is significant, this is a multi-faceted global organization with alot of cutting-edge technology. Let's hear about some more about some of these new developments.

    • View More Messages
 
JNJ
102.63+1.41(+1.39%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.